Verrica Pharma appoints Chris Chapman as CCO

13 February 2026

US dermatology specialist Verrica Pharmaceuticals (Nasdaq: VRCA) has announced the appointment of Chris Chapman as its chief commercial officer (CCO).

“It is my pleasure to welcome Chris Chapman to the Verrica team as our new Chief Commercial Officer,” said Jayson Rieger, president and chief executive. “Chris has an extraordinary track record of successfully commercializing several products in dermatology and other specialties, and has had success in building and leading commercial organizations in dynamic and competitive markets. I am confident that Chris’ commercial acumen will broaden access to Ycanth [cantharidin] for molluscum patients and bring critical insights to our global Phase III program for common warts as well as the development of VP-315, our novel oncolytic peptide for basal cell carcinoma,” he added.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK